The diagnostic challenge of a rare malignancy called neuroblastoma: a clinical case report

Jenish Lakhabhai Vekariya; Olga Zenevich Valerievna; Vishrutkumar Girishbhai Sangani; Sujal Dineshbhai Solanki

doi:10.18203/2349-3933.ijam20261880

Authors

Jenish Lakhabhai Vekariya Department of Paediatrics, Grodno State Medical University, Grodno, Belarus
Olga Zenevich Valerievna Department of Paediatrics, Grodno State Medical University, Grodno, Belarus
Vishrutkumar Girishbhai Sangani Department of Paediatrics, Grodno State Medical University, Grodno, Belarus
Sujal Dineshbhai Solanki Department of Paediatrics, Grodno State Medical University, Grodno, Belarus

DOI:

https://doi.org/10.18203/2349-3933.ijam20261880

Keywords:

Neuroblastoma, Retroperitoneal fibrosis, Left hydronephrosis grade 2-3

Abstract

Neuroblastoma is a paediatric tumor that originates from neuroblasts. An interesting case report from Grodno of a child with mixed etiology showed some findings for neuroblastoma and some for Ormond's disease because the patient also has retroperitoneal fibrosis. Although both could be connected or can be separate diseases. Disease started with congenital anomaly of grade 2-3 left hydronephrosis and space occupying lesion in the retroperitoneal space (neuroblastoma). Then additional soft tissue tumor-like mass found near abdominal aorta and in the retroperitoneal space (Ormond’s disease). This could be neuroblastoma of retroperitoneal space. Although neuroblastoma can be a separate disease or it could be in association with another disease, this article discusses the abnormal clinical presentation of neuroblastoma.

Metrics

Metrics Loading ...

References

Otte J, Dyberg C, Pepich A, Johnsen JI. MYCN Function in Neuroblastoma Development. Front Oncol. 2021;10:624079. DOI: https://doi.org/10.3389/fonc.2020.624079

Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369-86. DOI: https://doi.org/10.1080/14737140.2017.1285230

Tsubota S, Kadomatsu K. Origin and mechanism of neuroblastoma. Oncoscience. 2017;4(8):70-2. DOI: https://doi.org/10.18632/oncoscience.360

Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018;372(2):195-209. DOI: https://doi.org/10.1007/s00441-018-2821-2

Eisenhofer G, Peitzsch M, Bechmann N, Huebner A. Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma. Front Endocrinol. 2022;13:901760. DOI: https://doi.org/10.3389/fendo.2022.901760

Ponzoni M, Bachetti T, Corrias MV, Brignole C, Pastorino F, Calarco E, et al. Recent advances in the developmental origin of neuroblastoma: an overview. J Exp Clin Cancer Res. 2022;41(1):92. DOI: https://doi.org/10.1186/s13046-022-02281-w

Maris JM. Recent Advances in Neuroblastoma. N Engl J Med. 2010;362(23):2202-11. DOI: https://doi.org/10.1056/NEJMra0804577

Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P, et al. MYCN impact on high-risk neuroblastoma: from diagnosis and prognosis to targeted treatment. Cancers (Basel). 2022;14(18):4421. DOI: https://doi.org/10.3390/cancers14184421

Aktaş S. Anti-Cancer treatments affecting PI3K/Akt/Mtor and Ras/MAPK pathways in neuroblastoma. Dev Exp Health Med. 2025;39(3):153-63. DOI: https://doi.org/10.18614/dehm.1751044

Fati F, Pulvirenti R, Paraboschi I, Martucciello G. Surgical Approaches to Neuroblastoma: Review of the Operative Techniques. Children. 2021;8(6):446. DOI: https://doi.org/10.3390/children8060446